Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

176
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
176
Cancer Therapies02:49

Cancer Therapies

9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

5.8K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrative multi-omics analysis identifies histone methyltransferase SUV420H2 as a prognostic biomarker in clear cell renal cell carcinoma.

Discover oncology·2026
Same author

Beyond Hemoglobinopathies: Non-Hemoglobinopathy Causes of Transfusion-Dependent Anemia in Children.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion·2026
Same author

<b>A Rare Pediatric Case of Immunodeficiency 76 and its Progression to Acute Myeloid Leukemia</b>.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion·2026
Same author

Targeting mitochondria as a potential therapeutic strategy against radioresistance in cancer.

Frontiers in oncology·2026
Same author

Bevacizumab added to conventional induction chemotherapy for children with high risk neuroblastoma (BRAVEN trial).

Discover oncology·2026
Same author

Integrated Genomic Profiling of Newly Diagnosed and Relapsed Acute Myeloid Leukemia Identifies Driver Genes, Mutational Signatures, and Therapeutic Targets.

Cancers·2026

Related Experiment Video

Updated: Jan 9, 2026

A Brain Tumor/Organotypic Slice Co-culture System for Studying Tumor Microenvironment and Targeted Drug Therapies
10:13

A Brain Tumor/Organotypic Slice Co-culture System for Studying Tumor Microenvironment and Targeted Drug Therapies

Published on: November 7, 2015

11.6K

Pediatric tumor microenvironment: developmental dynamics and therapy resistance.

Noreen Grace George1,2, Bhavika Rishi1, Himanshu Dhanda1,2

  • 1Indian Council of Medical Research-National Institute of Child Health Development Research, New Delhi, India.

Frontiers in Oncology
|December 8, 2025
PubMed
Summary

Pediatric cancers feature unique tumor microenvironments (TME) influenced by child development, driving immune evasion and therapy resistance. Tailored, age-informed treatments integrating developmental biology are crucial for better outcomes.

Keywords:
ECMdevelopmental oncologyimmune checkpoint inhibitionpediatric tumor microenvironmenttherapeutic resistance

More Related Videos

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device
07:44

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device

Published on: May 2, 2025

762
Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation
10:24

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation

Published on: September 19, 2019

6.7K

Related Experiment Videos

Last Updated: Jan 9, 2026

A Brain Tumor/Organotypic Slice Co-culture System for Studying Tumor Microenvironment and Targeted Drug Therapies
10:13

A Brain Tumor/Organotypic Slice Co-culture System for Studying Tumor Microenvironment and Targeted Drug Therapies

Published on: November 7, 2015

11.6K
Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device
07:44

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device

Published on: May 2, 2025

762
Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation
10:24

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation

Published on: September 19, 2019

6.7K

Area of Science:

  • Pediatric oncology
  • Developmental biology
  • Cancer immunology

Background:

  • Pediatric cancers arise in unique developmental contexts, differing significantly from adult malignancies.
  • The pediatric tumor microenvironment (TME) is shaped by evolving immune systems, stromal dynamics, and developmental factors.
  • These specialized niches promote immune evasion, therapy resistance, and disease progression in childhood cancers.

Purpose of the Study:

  • To review how developmental processes interact with tumor biology in pediatric cancers.
  • To explore mechanisms driving immune evasion and treatment failure in the pediatric TME.
  • To highlight advancements and the need for age-informed therapeutic strategies.

Main Methods:

  • Literature review focusing on developmental biology and pediatric tumor microenvironments.
  • Analysis of key mechanisms like extracellular matrix remodeling, metabolic reprogramming, and epigenetic plasticity.
  • Examination of emerging nanomedicine and circulating marker applications.

Main Results:

  • Developmental processes critically influence the pediatric TME, fostering tumor growth and immune suppression.
  • Extracellular matrix remodeling, metabolic reprogramming, and epigenetic plasticity are key drivers of treatment failure.
  • Nanomedicine and circulating markers offer potential for more precise, age-specific interventions.

Conclusions:

  • Understanding the pediatric TME's developmental underpinnings is essential for effective cancer treatment.
  • Therapeutic strategies must be age-informed, considering the unique risks and benefits of the pediatric TME.
  • Integrating developmental biology with tumor ecosystem knowledge is vital for advancing pediatric cancer care.